All In MedTech

FDA Clearance Tracker · P860022-S054

BOSTON EQUEALENS RIGID GAS/II RIGID GAS PERMEABLE CONTACT LENS

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 6, 2002 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 6, 2002

Approved

Time to decision

96 days

Received Jan 30, 2002. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P860022-S054
Device name
BOSTON EQUEALENS RIGID GAS/II RIGID GAS PERMEABLE CONTACT LENS
Applicant
Bausch & Lomb
Applicant location
Rochester, NY
Received
Jan 30, 2002
Decided
May 6, 2002
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P860022

Device type

Device class
Class III
Regulation
21 CFR 886.5916
Specialty
Ophthalmology

Every decision under product code MWL

FDA's approval statement

As written in FDA's record.

APPROVAL FOR AN ASPHERIC DESIGN FOR EXTENDED WEAR AND LABELING CHANGES FOR THE DEVICE. REQUESTED LABELING CHANGES INCLUDE: 1) CHANGE FROM THE TITLE "PATIENT INSTRUCTIONS" TO "PATIENT CARE GUIDE". 2) UPDATE THE PRESCRIPTION CAUTION STATEMENT. 3) MODIFY THE PRODUCT DESCRIPTION SECTION OF THE PACKAGE INSERT AND PROFESSIONAL FITTING AND INFORMATION GUIDE AS FOLLOWS: A) ADD THE DESCRIPTIONS FOR BOTH THE ASPHERIC DESIGN (EXTENDED AND DAILY WEAR) AND THE PREVIOUSLY APPROVED BIFOCAL LENS (DAILY WEAR ONLY) AND SPECIFY DAILY WEAR FOR THE TORIC AND BIFOCAL DESIGNS; B) REMOVE FROM THESE PRODUCT DESCRIPTION SECTIONS THE PHRASE "WITHOUT UV" BECAUSE THIS OPTION IS NO LONGER AVAILABLE; AND C) CHANGE THE COLOR NAME OF THE BLUE LENS MATERIAL FROM "DARK BLUE" TO "ELECTRIC BLUE". 4) CORRECT THE MANUFACTURER'S ADDRESS. 5) UPDATE THE WORDING OF THE UV WARNING AND CLARIFY THE EXTENDED WEAR INDICATION AS IN THE INDICATION STATED BELOW."THE BOSTON EQUALENS (ITAFLUOROFOCON A) RGP CONTACT LENS IS INDICATED FOR DAILY OR EXTENDED WEAR FROM 1 TO 7 DAYS BETWEEN REMOVALS FOR CLEANING AND DISINFECTION AS RECOMMENDED BY THE EYE CARE PRACTITIONER. THE LENS IS INDICATED FOR EXTENDED WEAR FOR THE CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA AND HYPEROPIA) IN NOT-APHAKIC PERSONS WITH NON-DISEASED EYES IN POWERS FROM -20.00D TO +12.00D. THE LENS IS INDICATED FOR DAILY WEAR FOR THE CORRECTION OF REFRACTIVE AMETROPIA (MYOPIA, HYPEROPIA, ASTIGMATISM AND PRESBYOPIA) IN APHAKIC AND NOT-APHAKIC PERSONS WITH NON-DISEASED EYES. THE LENS MAY BE DISINFECTED USING A CHEMICAL DISINFECTION SYSTEM ONLY."

Source documents

Other decisions for Bausch & Lomb

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.